TrianglePD-L1 t-haNK (NCT06239220)
PD-L1 t-haNK trial for Head and Neck Cancer (NCT06239220). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HPV-negative head-and-neck squamous cancer that is recurrent/metastatic or incurable locally advanced. One or two previous systemic treatment lines, including anti-PD-1/L1 therapy, are required.
The idea: combine modified donor-derived natural-killer cells with NAI, an immune-stimulating protein, and cetuximab, a targeted antibody. The combination aims to strengthen cancer-directed immune-cell activity. Cells and cetuximab are infused; NAI is injected under the skin, every two weeks. Doses may decrease for toxicity. Follow-up extends to 15 years.
This phase 2 study plans 25 patients. Michael Dennis leads at two recruiting Boston sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.